By staff writers
February 21, 2018

Medical software developer Densitas is directing attention to a recent review that validated the clinical use of its automated breast-density measurement software to help stratify patients based on their risk for breast cancer.

The findings were published online February 5 in Breast Cancer Research.

Researchers from the University of Manchester in the U.K. reviewed five different methods for assessing breast density in 366 women participating in the Predicting Risk of Cancer at Screening (PROCAS) study. They found that both the Densitas software and the VolparaDensity algorithm (Volpara Solutions) could be used practically in breast cancer risk models due to the strong association of these density measurements with the risk of breast cancer.

Visual and semiautomated density assessments also show strong relationships with breast cancer risk, but the researchers judged these approaches to be impractical in population-based screening, Densitas said.

The company also said that several scientific and poster presentations at ECR 2018 in March will further confirm the clinical validation of its breast density software.

Densitas highlights research at BSBR meeting
Medical device firm Densitas said two research studies involving its DM-Density automated breast density software were presented at this week's British...
Densitas highlights breast density research at ECR
Medical device firm Densitas is highlighting two research studies using its breast density assessment software that were presented at this week's ECR...
Densitas receives CE Mark, Canadian clearance
Medical device firm Densitas has received the CE Mark from the European Commission and a medical device license from Health Canada for its DM-Density...
Densitas highlights research presentations at ECR
Densitas is highlighting presentations given at ECR 2015 in Vienna about its breast density assessment software.

Copyright © 2018

Last Updated hh 2/22/2018 3:40:04 PM